Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
{{output}}
Background: At the primary progression-free (PFS) analysis, the phase 3 EMBER-3 trial in endocrine pretreated patients with ER+, HER2- advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant vs. standa... ...
